

EVH_MP_2518.MPC Collagenase Clostridium Histolyticum

Maryland Physicians Care considers **Collagenase Clostridium Histolyticum** medically necessary for the following indications in adults (It is not known if it is safe and effective in children under the age of 18):

- To treat adults with documented Dupuytren's contracture with a palpable cord ^(1,2)
 - Up to two joints in the same hand may be treated during a single treatment visit
 - Injections and finger extension procedures may be administered up to three times per cord at approximately four-week intervals
 - Only one initial evaluation and management (E&M) service visit may be billed for the series of injections used to treat the entire Dupuytren's contracture of one hand
 - E&M services billed on the same day of service as an injection must be for a significant and separately identifiable service unless it is the initial evaluation for the series of injections as indicated above
 - More than two follow-up visits per joint level injection of a cord may be subject to review. Documentation should be kept on file and available upon request
 - The injection should only be administered by a healthcare provider experienced in injection procedures of the hand and in the treatment of Dupuytren's contracture
 - The same physician should perform the injection and the manipulation/stretching procedure for Dupuytren's contracture
- To treat adults with documented Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy ⁽³⁾
 - Injections for Peyronie's disease are limited to four treatment cycles. Each treatment cycle consists of two Collagenase Clostridium Histolyticum injections and one penile remodeling procedure performed by a health care professional.
 - Collagenase Clostridium Histolyticum is only available for the treatment of Peyronie's disease through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS)

Limitations

- Collagenase Clostridium Histolyticum is not covered for any other indication, including adhesive capsulitis
- Member should be free of any chronic muscular, neurological or neuromuscular disorder affecting the hands

EVH_MP_2518.MPC Collagenase Clostridium Histolyticum

Policy Number: EVH_MP_2518.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

- Should be used with caution for members on anticoagulants (except for low-dose aspirin)
- Redirection of the needle in the subcutaneous or intralesional tissue does not constitute a separate injection

Codes

CPT Codes / HCPCS Codes / ICD-10 Codes	
Code	Description
J0775	Injection, collagenase, clostridium histolyticum, 0.01 mg
20527	Injection, enzyme (e.g., collagenase), palmar fascial cord (i.e., Dupuytren's contracture)
26341	Manipulation, palmar fascial cord (i.e., Dupuytren's cord), post enzyme injection (e.g., collagenase), single cord
54200	Injection procedure for Peyronie disease
ICD-10 codes covered if selection criteria are met:	
M72.0	Palmar fascial fibromatosis [Dupuytren]
N48.6	Induration penis plastica

Policy History

Date	Summary
February 19, 2026	<ul style="list-style-type: none"> • This guideline was renumbered and renamed from MP.097 Xiaflex (Collagenase Clostridium Histolyticum) • Annual review - Formatting updates throughout; replaced Xiaflex with Collagenase Clostridium Histolyticum throughout; moved limitations specific to treatment up to Indications; additional updates to Indications and Limitations sections; updated description of procedure code J0775 and ICD-10 codes M72.0 and N48.6; updated References; added Policy History Log

References

1. Pess GM, Hurley D, Verheyden JR, Benhaim P. Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based

EVH_MP_2518.MPC Collagenase Clostridium Histolyticum

Policy Number: EVH_MP_2518.MPC

Last Review Date: 02/19/2026

Effective Date: 03/01/2026

Consensus Study. *J Hand Surg Glob Online*. 2024;6(2):151-158.

doi:10.1016/j.jhsg.2023.10.011

2. Sandler AB, Scanaliato JP, Dennis T, et al. Treatment of Dupuytren's Contracture With Collagenase: A Systematic Review. *HAND*. 2022;17(5):815-824. doi: 10.1177/1558944720974119.
3. Guo Y, Yang Y, Mao Q, et al. Efficacy of collagenase Clostridium histolyticum combination therapies for Peyronie's disease: a systematic review and meta-analysis. *Sex Med Rev*. 2024;12(3):497-504. doi: 10.1093/sxmrev/qeae025.

Disclaimer

Maryland Physicians Care medical payment and prior authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. The policies constitute only the reimbursement and coverage guidelines of Maryland Physicians Care and its affiliated managed care entities. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies.

Maryland Physicians Care reserves the right to review and update the medical payment and prior authorization guidelines in its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.

These policies are the proprietary information of Maryland Physicians Care. Any sale, copying, or dissemination of said policies is prohibited.